In conclusion, the results of the present study indicate that the IAP inhibitor LBW242 is active in mediating inhibition of ovarian cancer cells, particularly when acting in combination with TRAIL or with some antineoplastic drugs. Here, TNFSF10 is linked to ovarian carcinoma.